Journal of Critical Care
Volume 25, Issue 2 , Pages 270-275, June 2010

Troponin-I as a prognosticator of mortality in severe sepsis patients☆☆☆★

  • Jijo John, MD

      Affiliations

    • University of Oklahoma Health Sciences Center, Pulmonary/Critical Care Medicine, Oklahoma City, OK 73104, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 405 271 6173; fax: +1 405 271 5892.
    • ,
  • D. Bradley Woodward, MD

      Affiliations

    • Eli Lilly and Company, Cardiovascular/Critical Care, Lilly Corporate Center, Indianapolis, IN 46285, USA
    • ,
  • Yanping Wang, PhD

      Affiliations

    • Eli Lilly and Company, Cardiovascular/Critical Care, Lilly Corporate Center, Indianapolis, IN 46285, USA
    • ,
  • S. Betty Yan, PhD

      Affiliations

    • Eli Lilly and Company, Cardiovascular/Critical Care, Lilly Corporate Center, Indianapolis, IN 46285, USA
    • ,
  • Diana Fisher, MS

      Affiliations

    • Eli Lilly and Company, Cardiovascular/Critical Care, Lilly Corporate Center, Indianapolis, IN 46285, USA
    • ,
  • Gary T. Kinasewitz, MD

      Affiliations

    • University of Oklahoma Health Sciences Center, Pulmonary/Critical Care Medicine, Oklahoma City, OK 73104, USA
    • ,
  • Darell Heiselman, DO

      Affiliations

    • Eli Lilly and Company, Cardiovascular/Critical Care, Lilly Corporate Center, Indianapolis, IN 46285, USA

published online 11 February 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Work was performed at Eli Lilly and Company, Cardiovascular/Critical Care, Lilly Corporate Center, Indianapolis, IN 46285.

☆☆ Financial support was provided by Eli Lilly and Company.

★ Disclosures: Dr Kinasewitz is a speaker for Eli Lilly's lecture bureau. Drs Woodward, Wang, Yan, and Heiselman and Ms Fisher are employees and shareholders of Eli Lilly and Company. Eli Lilly and Company is the maker of drotrecogin alfa (activated).

PII: S0883-9441(09)00287-1

doi:10.1016/j.jcrc.2009.12.001

Journal of Critical Care
Volume 25, Issue 2 , Pages 270-275, June 2010

Article Tools